Differential vulnerability of neurons in Huntington’s disease: the role of cell type‐specific features

J. Neurochem. (2010) 113, 1073–1091.

[1]  L. Menalled,et al.  Knock-in mouse models of Huntington’s disease , 2005, NeuroRX.

[2]  Chuan-en Wang,et al.  Mutant Huntingtin in Glial Cells Exacerbates Neurological Symptoms of Huntington Disease Mice* , 2010, The Journal of Biological Chemistry.

[3]  Y. Barde,et al.  Global Deprivation of Brain-Derived Neurotrophic Factor in the CNS Reveals an Area-Specific Requirement for Dendritic Growth , 2010, The Journal of Neuroscience.

[4]  Peng Yu,et al.  Altered white matter microstructure in the corpus callosum in Huntington's disease: Implications for cortical “disconnection” , 2010, NeuroImage.

[5]  A. Orr,et al.  Impaired mitochondrial trafficking in Huntington's disease. , 2010, Biochimica et biophysica acta.

[6]  Yuyu Song,et al.  Axonal Transport Defects in Neurodegenerative Diseases , 2009, The Journal of Neuroscience.

[7]  N. Déglon,et al.  Diminished hippocalcin expression in Huntington’s disease brain does not account for increased striatal neuron vulnerability as assessed in primary neurons , 2009, Journal of neurochemistry.

[8]  V. Silani,et al.  Huntington's disease: The current state of research with peripheral tissues , 2009, Experimental Neurology.

[9]  Chun-Fang Huang,et al.  Pathogenic Huntingtin Inhibits Fast Axonal Transport by Activating JNK3 and Phosphorylating Kinesin , 2009, Nature Neuroscience.

[10]  P. Reddy,et al.  Mitochondrial structural and functional dynamics in Huntington's disease , 2009, Brain Research Reviews.

[11]  J. Marsh,et al.  Live axonal transport disruption by mutant huntingtin fragments in Drosophila motor neuron axons , 2009, Neurobiology of Disease.

[12]  Kurt E. Weaver,et al.  Longitudinal diffusion tensor imaging in Huntington's Disease , 2009, Experimental Neurology.

[13]  N. Déglon,et al.  Implication of the JNK pathway in a rat model of Huntington's disease , 2009, Experimental Neurology.

[14]  M. Farrer,et al.  DCTN1 mutations in Perry syndrome , 2009, Nature Genetics.

[15]  L. Goldstein,et al.  Enhanced Sensitivity of Striatal Neurons to Axonal Transport Defects Induced by Mutant Huntingtin , 2008, The Journal of Neuroscience.

[16]  S. Browne,et al.  Mitochondria and Huntington's Disease Pathogenesis , 2008, Annals of the New York Academy of Sciences.

[17]  R. Atwal,et al.  Huntington’s disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases , 2008, The FEBS journal.

[18]  Paul Greengard,et al.  Cell type–specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs , 2008, Nature Neuroscience.

[19]  Carlos Cepeda,et al.  Full-Length Human Mutant Huntingtin with a Stable Polyglutamine Repeat Can Elicit Progressive and Selective Neuropathogenesis in BACHD Mice , 2008, The Journal of Neuroscience.

[20]  Brendan H. Lee,et al.  Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin , 2008, The Journal of cell biology.

[21]  L. Massieu,et al.  Excitotoxic neuronal death and the pathogenesis of Huntington's disease. , 2008, Archives of Medical Research.

[22]  He Li,et al.  N-Terminal Mutant Huntingtin Associates with Mitochondria and Impairs Mitochondrial Trafficking , 2008, The Journal of Neuroscience.

[23]  Yuwu Jiang,et al.  Clinical and genetic study in Chinese patients with Alexander disease. , 2008 .

[24]  A. Jennifer Morton,et al.  Atrophy and degeneration in sciatic nerve of presymptomatic mice carrying the Huntington's disease mutation , 2008, Brain Research.

[25]  J. Vonsattel,et al.  Huntington disease models and human neuropathology: similarities and differences , 2007, Acta Neuropathologica.

[26]  J. Cha,et al.  Transcriptional signatures in Huntington's disease , 2007, Progress in neurobiology.

[27]  Xi Chen,et al.  Dopaminergic Signaling and Striatal Neurodegeneration in Huntington's Disease , 2007, The Journal of Neuroscience.

[28]  H. Zoghbi,et al.  Trinucleotide repeat disorders. , 2007, Annual review of neuroscience.

[29]  M. MacDonald,et al.  Unbiased Gene Expression Analysis Implicates the huntingtin Polyglutamine Tract in Extra-mitochondrial Energy Metabolism , 2007, PLoS genetics.

[30]  Wenya Linda Bi,et al.  Triplet repeat mutation length gains correlate with cell-type specific vulnerability in Huntington disease brain. , 2007, Human molecular genetics.

[31]  J. Kordower,et al.  Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease , 2007, Neurobiology of Disease.

[32]  Carlos Cepeda,et al.  The corticostriatal pathway in Huntington's disease , 2007, Progress in Neurobiology.

[33]  F. Walker.  Huntington's disease. , 2007, Lancet.

[34]  E. Cattaneo,et al.  Role of brain-derived neurotrophic factor in Huntington's disease , 2007, Progress in Neurobiology.

[35]  Xiao-Jiang Li.  The early cellular pathology of Huntington’s disease , 1999, Molecular Neurobiology.

[36]  Jeffrey H Kordower,et al.  Animal models of Huntington's disease. , 2007, ILAR journal.

[37]  O. Steward,et al.  Differential susceptibility to striatal neurodegeneration induced by quinolinic acid and kainate in inbred, outbred and hybrid mouse strains , 2006, The European journal of neuroscience.

[38]  E. Thomas,et al.  Striatal specificity of gene expression dysregulation in Huntington's disease , 2006, Journal of neuroscience research.

[39]  J. Alberch,et al.  Cellular and molecular mechanisms involved in the selective vulnerability of striatal projection neurons in Huntington's disease. , 2006, Histology and histopathology.

[40]  Dale E. Bredesen,et al.  Cell death in the nervous system , 2006, Nature.

[41]  K. Jellinger.  Challenges in neuronal apoptosis. , 2006, Current Alzheimer research.

[42]  H. McBride,et al.  Mitochondria: More Than Just a Powerhouse , 2006, Current Biology.

[43]  G. Pigino,et al.  JNK mediates pathogenic effects of polyglutamine-expanded androgen receptor on fast axonal transport , 2006, Nature Neuroscience.

[44]  P. Klivényi,et al.  Behaviour changes in a transgenic model of Huntington's disease , 2006, Behavioural Brain Research.

[45]  M. Mattson,et al.  Ageing and neuronal vulnerability , 2006, Nature Reviews Neuroscience.

[46]  Katalin Illes,et al.  Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. , 2006, Human molecular genetics.

[47]  L. Raymond,et al.  Selective neuronal degeneration in Huntington's disease. , 2006, Current topics in developmental biology.

[48]  S. Dunnett,et al.  Pharmaceutical, cellular and genetic therapies for Huntington's disease. , 2006, Clinical science.

[49]  A. Parent,et al.  Relationship between axonal collateralization and neuronal degeneration in basal ganglia. , 2006, Journal of neural transmission. Supplementum.

[50]  M. MacDonald,et al.  HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. , 2005, Human molecular genetics.

[51]  C. Pagès,et al.  Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[52]  K. Fischbeck,et al.  Distal spinal and bulbar muscular atrophy caused by dynactin mutation , 2005, Annals of neurology.

[53]  G. Pigino,et al.  Polyglutamine expansion diseases: failing to deliver. , 2005, Trends in molecular medicine.

[54]  E. Wagner,et al.  Specific pathophysiological functions of JNK isoforms in the brain , 2005, The European journal of neuroscience.

[55]  P. Wesseling,et al.  Expression pattern of apoptosis-related markers in Huntington’s disease , 2005, Acta Neuropathologica.

[56]  Bin Zhang,et al.  Axonal transport defects: a common theme in neurodegenerative diseases , 2005, Acta Neuropathologica.

[57]  J. Caboche,et al.  Expanded huntingtin activates the C-JUN N TERMINAL KINASE/C-JUN pathway prior to aggregate formation in striatal neurons in culture , 2004, Neuroscience.

[58]  Carlos Cepeda,et al.  Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect , 2004, Trends in Neurosciences.

[59]  Mark R. Segal,et al.  Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death , 2004, Nature.

[60]  Shihua Li,et al.  Huntington and its Role in Neuronal Degeneration , 2004, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[61]  E. Seeberg,et al.  Mutant Huntingtin Impairs Axonal Trafficking in Mammalian Neurons In Vivo and In Vitro , 2004, Molecular and Cellular Biology.

[62]  J. Kordower,et al.  Early changes in Huntington’s disease patient brains involve alterations in cytoskeletal and synaptic elements , 2004, Journal of neurocytology.

[63]  G. Mengod,et al.  Brain-Derived Neurotrophic Factor Regulates the Onset and Severity of Motor Dysfunction Associated with Enkephalinergic Neuronal Degeneration in Huntington's Disease , 2004, The Journal of Neuroscience.

[64]  Fabrice P Cordelières,et al.  Huntingtin Controls Neurotrophic Support and Survival of Neurons by Enhancing BDNF Vesicular Transport along Microtubules , 2004, Cell.

[65]  Sarah A. J. Reading,et al.  Functional brain changes in presymptomatic Huntington's disease , 2004, Annals of neurology.

[66]  M. Beal,et al.  Experimental therapeutics in transgenic mouse models of Huntington's disease , 2004, Nature Reviews Neuroscience.

[67]  J. Gorski,et al.  Early Striatal Dendrite Deficits followed by Neuron Loss with Advanced Age in the Absence of Anterograde Cortical Brain-Derived Neurotrophic Factor , 2004, The Journal of Neuroscience.

[68]  R. Bonelli,et al.  A review of the treatment options for Huntington’s disease , 2004, Expert opinion on pharmacotherapy.

[69]  J. Littleton,et al.  Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[70]  M. Tymianski,et al.  Molecular mechanisms underlying specificity of excitotoxic signaling in neurons. , 2004, Current molecular medicine.

[71]  D. Mann,et al.  The topographic distribution of brain atrophy in Huntington's disease and progressive supranuclear palsy , 2004, Acta Neuropathologica.

[72]  H. Heinsen,et al.  Cortical and striatal neurone number in Huntington's disease , 2004, Acta Neuropathologica.

[73]  Elizabeth Evans,et al.  Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis. , 2003, Human molecular genetics.

[74]  Marjan S. Bolouri,et al.  Integrated Analysis of Protein Composition, Tissue Diversity, and Gene Regulation in Mouse Mitochondria , 2003, Cell.

[75]  Harry T Orr,et al.  Regional differences of somatic CAG repeat instability do not account for selective neuronal vulnerability in a knock-in mouse model of SCA1. , 2003, Human molecular genetics.

[76]  Christine Van Broeckhoven,et al.  Pathogenesis of polyglutamine disorders: aggregation revisited. , 2003, Human molecular genetics.

[77]  J. Brandt,et al.  Predictors of neuropathological severity in 100 patients with Huntington's disease , 2003, Annals of neurology.

[78]  Scott T. Brady,et al.  Neuropathogenic Forms of Huntingtin and Androgen Receptor Inhibit Fast Axonal Transport , 2003, Neuron.

[79]  Richard G. Brusch,et al.  Disruption of Axonal Transport by Loss of Huntingtin or Expression of Pathogenic PolyQ Proteins in Drosophila , 2003, Neuron.

[80]  D. Rubinsztein,et al.  Huntington's disease: molecular basis of neurodegeneration , 2003, Expert Reviews in Molecular Medicine.

[81]  M. Okun.  Huntington’s Disease: What We Learned From the Original Essay , 2003, The neurologist.

[82]  A. Spada,et al.  Polyglutamines Placed into Context , 2003, Neuron.

[83]  I. Mitchell,et al.  The Differential Susceptibility of Specific Neuronal Populations: Insights from Huntington's Disease , 2003, IUBMB life.

[84]  K. Merienne,et al.  Polyglutamine Expansion Induces a Protein-damaging Stress Connecting Heat Shock Protein 70 to the JNK Pathway* , 2003, The Journal of Biological Chemistry.

[85]  Yasushi Hiraoka,et al.  Mutations in Dynein Link Motor Neuron Degeneration to Defects in Retrograde Transport , 2003, Science.

[86]  M. Vila,et al.  Neurological diseases: Targeting programmed cell death in neurodegenerative diseases , 2003, Nature Reviews Neuroscience.

[87]  Thomas Walther,et al.  Transgenic rat model of Huntington's disease. , 2003, Human molecular genetics.

[88]  Shin J. Oh,et al.  Mutant dynactin in motor neuron disease , 2003, Nature Genetics.

[89]  Carlos Cepeda,et al.  Transient and Progressive Electrophysiological Alterations in the Corticostriatal Pathway in a Mouse Model of Huntington's Disease , 2003, The Journal of Neuroscience.

[90]  M. Pericak-Vance,et al.  A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10). , 2002, American journal of human genetics.

[91]  D. Rubinsztein,et al.  Glycogen Synthase Kinase-3β Inhibitors Prevent Cellular Polyglutamine Toxicity Caused by the Huntington's Disease Mutation* , 2002, The Journal of Biological Chemistry.

[92]  M. Birnbaum,et al.  Akt1 Regulates a JNK Scaffold during Excitotoxic Apoptosis , 2002, Neuron.

[93]  G. Bates,et al.  Abnormal Phosphorylation of Synapsin I Predicts a Neuronal Transmission Impairment in the R6/2 Huntington's Disease Transgenic Mice , 2002, Molecular and Cellular Neuroscience.

[94]  James R. Burke,et al.  Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines , 2002, Nature Neuroscience.

[95]  Fabrice P Cordelières,et al.  The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. , 2002, Developmental cell.

[96]  Christopher A. Ross,et al.  Lentiviral-Mediated Delivery of Mutant Huntingtin in the Striatum of Rats Induces a Selective Neuropathology Modulated by Polyglutamine Repeat Size, Huntingtin Expression Levels, and Protein Length , 2002, The Journal of Neuroscience.

[97]  Emmanuel Brouillet,et al.  The Mitochondrial Toxin 3-Nitropropionic Acid Induces Striatal Neurodegeneration via a c-Jun N-Terminal Kinase/c-Jun Module , 2002, The Journal of Neuroscience.

[98]  S. Brady,et al.  Regulation of Kinesin: Implications for Neuronal Development , 2001, Developmental Neuroscience.

[99]  M. Chesselet,et al.  Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. , 2001, Journal of neurophysiology.

[100]  C. Cepeda,et al.  Changes in Cortical and Striatal Neurons Predict Behavioral and Electrophysiological Abnormalities in a Transgenic Murine Model of Huntington's Disease , 2001, The Journal of Neuroscience.

[101]  J. Schiefer,et al.  Evaluation of R6/2 HD transgenic mice for therapeutic studies in Huntington's disease: behavioral testing and impact of diabetes mellitus , 2001, Behavioural Brain Research.

[102]  C. Cepeda,et al.  NMDA receptor function in mouse models of Huntington disease , 2001, Journal of neuroscience research.

[103]  H Li,et al.  Huntingtin Aggregate-Associated Axonal Degeneration is an Early Pathological Event in Huntington's Disease Mice , 2001, The Journal of Neuroscience.

[104]  A. Gordon,et al.  Objective assessment of progression in Huntington’s disease: A 3-year follow-up study , 2001, Neurology.

[105]  I. Kanazawa,et al.  Age‐dependent and tissue‐specific CAG repeat instability occurs in mouse knock‐in for a mutant Huntington's disease gene , 2001, Journal of neuroscience research.

[106]  Blair R. Leavitt,et al.  Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease , 2001, Science.

[107]  Gareth W. Price,et al.  Activated JNK Phosphorylates the C-terminal Domain of MLK2 That Is Required for MLK2-induced Apoptosis* , 2001, The Journal of Biological Chemistry.

[108]  K. Sieradzan,et al.  The selective vulnerability of nerve cells in Huntington's disease , 2001, Neuropathology and applied neurobiology.

[109]  E. Tolosa,et al.  Expression of Brain-Derived Neurotrophic Factor in Cortical Neurons Is Regulated by Striatal Target Area , 2001, The Journal of Neuroscience.

[110]  A. Tobin,et al.  Huntington's disease: the challenge for cell biologists. , 2000, Trends in cell biology.

[111]  A. Parent,et al.  Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington’s disease , 2000, Brain Research Reviews.

[112]  P. Shelbourne,et al.  Dramatic mutation instability in HD mouse striatum: does polyglutamine load contribute to cell-specific vulnerability in Huntington's disease? , 2000, Human molecular genetics.

[113]  S B Dunnett,et al.  Abnormal Synaptic Plasticity and Impaired Spatial Cognition in Mice Transgenic for Exon 1 of the Human Huntington's Disease Mutation , 2000, The Journal of Neuroscience.

[114]  P. Greengard,et al.  Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[115]  W. Maragos,et al.  Neuronal cell death in Huntington’s disease: a potential role for dopamine , 2000, Trends in Neurosciences.

[116]  C A Ross,et al.  Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. , 2000, Human molecular genetics.

[117]  J. Penney,et al.  Expression of NMDA receptor subunit mRNAs in neurochemically identified projection and interneurons in the human striatum , 2000, The Journal of comparative neurology.

[118]  G. Sobue,et al.  An autopsy case with clinically and molecular genetically diagnosed Huntington's disease with only minimal non-specific neuropathological findings. , 2000, Clinical neuropathology.

[119]  S. Suhr,et al.  Intraneuronal Aggregate Formation and Cell Death after Viral Expression of Expanded Polyglutamine Tracts in the Adult Rat Brain , 2000, The Journal of Neuroscience.

[120]  S. Hersch,et al.  Huntingtin aggregates may not predict neuronal death in Huntington's disease , 1999 .

[121]  A. Cooper,et al.  The selective vulnerability of striatopallidal neurons , 1999, Progress in Neurobiology.

[122]  A. Morton,et al.  Selective Discrimination Learning Impairments in Mice Expressing the Human Huntington's Disease Mutation , 1999, The Journal of Neuroscience.

[123]  M. Beal,et al.  Bioenergetics in Huntington's Disease , 1999, Annals of the New York Academy of Sciences.

[124]  J. D. de Yébenes,et al.  Clinical correlation of striatal 1H MRS changes in Huntington’s disease , 1999, Neurology.

[125]  Shihua Li,et al.  Cellular Defects and Altered Gene Expression in PC12 Cells Stably Expressing Mutant Huntingtin , 1999, The Journal of Neuroscience.

[126]  G P Bates,et al.  Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. , 1999, Human molecular genetics.

[127]  D. Goebel,et al.  NMDA receptor subunit gene expression in the rat brain: a quantitative analysis of endogenous mRNA levels of NR1Com, NR2A, NR2B, NR2C, NR2D and NR3A. , 1999, Brain research. Molecular brain research.

[128]  H. Heinsen,et al.  Nerve cell loss in the thalamic mediodorsal nucleus in Huntington’s disease , 1999, Acta Neuropathologica.

[129]  Alfredo Berardelli,et al.  Pathophysiology of chorea and bradykinesia in Huntington's disease , 1999, Movement disorders : official journal of the Movement Disorder Society.

[130]  Claire-Anne Gutekunst,et al.  Nuclear and Neuropil Aggregates in Huntington’s Disease: Relationship to Neuropathology , 1999, The Journal of Neuroscience.

[131]  D. Surmeier,et al.  Cellular Localization of Huntingtin in Striatal and Cortical Neurons in Rats: Lack of Correlation with Neuronal Vulnerability in Huntington’s Disease , 1999, The Journal of Neuroscience.

[132]  J. Penney,et al.  Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease. , 1999, Journal of neuropathology and experimental neurology.

[133]  Y. Liu.  Expression of Polyglutamine-expanded Huntingtin Activates the SEK1-JNK Pathway and Induces Apoptosis in a Hippocampal Neuronal Cell Line* , 1998, The Journal of Biological Chemistry.

[134]  Steven Finkbeiner,et al.  Huntingtin Acts in the Nucleus to Induce Apoptosis but Death Does Not Correlate with the Formation of Intranuclear Inclusions , 1998, Cell.

[135]  K. Neve,et al.  D2 Dopamine Receptors Stimulate Mitogenesis Through Pertussis Toxin‐Sensitive G Proteins and Ras‐Involved ERK and SAP/JNK Pathways in Rat C6‐D2L Glioma Cells , 1998, Journal of neurochemistry.

[136]  A. Tobin,et al.  Metabolic Compromise with Systemic 3-Nitropropionic Acid Produces Striatal Apoptosis in Sprague–Dawley Rats but Not in BALB/c ByJ Mice , 1998, Experimental Neurology.

[137]  Xuechu Zhen,et al.  D1 dopamine receptor agonists mediate activation of p38 mitogen-activated protein kinase and c-Jun amino-terminal kinase by a protein kinase A-dependent mechanism in SK-N-MC human neuroblastoma cells. , 1998, Molecular pharmacology.

[138]  J. Mandel,et al.  A cellular model that recapitulates major pathogenic steps of Huntington's disease. , 1998, Human molecular genetics.

[139]  Michael R. Hayden,et al.  The Influence of Huntingtin Protein Size on Nuclear Localization and Cellular Toxicity , 1998, The Journal of cell biology.

[140]  Shihua Li,et al.  Aggregation of N-terminal huntingtin is dependent on the length of its glutamine repeats. , 1998, Human molecular genetics.

[141]  C A Ross,et al.  Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. , 1998, Human molecular genetics.

[142]  S. W. Davies,et al.  Intranuclear Neuronal Inclusions in Huntington's Disease and Dentatorubral and Pallidoluysian Atrophy: Correlation between the Density of Inclusions andIT15CAG Triplet Repeat Length , 1998, Neurobiology of Disease.

[143]  Y. Smith,et al.  Microcircuitry of the direct and indirect pathways of the basal ganglia. , 1998, Neuroscience.

[144]  S. W. Davies,et al.  Nuclear inclusions in Huntington's disease. , 1997, Trends in cell biology.

[145]  K Naujoks,et al.  Regional, developmental and interspecies expression of the four NMDAR2 subunits, examined using monoclonal antibodies. , 1997, Brain research. Molecular brain research.

[146]  P. Rakic,et al.  Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene , 1997, Nature.

[147]  S. W. Davies,et al.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.

[148]  A. Graybiel,et al.  Neurochemical architecture of the human striatum , 1997, The Journal of comparative neurology.

[149]  Mark Turmaine,et al.  Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation , 1997, Cell.

[150]  C. Cain,et al.  Cellular delivery of human CNTF prevents motor and cognitive dysfunction in a rodent model of Huntington's disease. , 1997, Cell transplantation.

[151]  M. MacDonald,et al.  CAG repeat number governs the development rate of pathology in Huntington's disease , 1997, Annals of neurology.

[152]  M. Hayden,et al.  The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. , 1997, American journal of human genetics.

[153]  M. Beal,et al.  Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia , 1997, Annals of neurology.

[154]  Y. Kawaguchi.  Neostriatal cell subtypes and their functional roles , 1997, Neuroscience Research.

[155]  W. Cass.  Decreases in evoked overflow of dopamine in rat striatum after neurotoxic doses of methamphetamine. , 1997, The Journal of pharmacology and experimental therapeutics.

[156]  M. Perutz,et al.  Glutamine repeats and inherited neurodegenerative diseases: molecular aspects. , 1996, Current opinion in structural biology.

[157]  P G Bhide,et al.  Expression of Normal and Mutant Huntingtin in the Developing Brain , 1996, The Journal of Neuroscience.

[158]  J. Kordower,et al.  Implants of Encapsulated Human CNTF-Producing Fibroblasts Prevent Behavioral Deficits and Striatal Degeneration in a Rodent Model of Huntington’s Disease , 1996, The Journal of Neuroscience.

[159]  Í. Lopes-Cendes,et al.  Somatic mosaicism in the central nervous system in spinocerebellar ataxia type 1 and machado‐joseph disease , 1996, Annals of neurology.

[160]  J. Xuereb,et al.  The messenger RNAs for the N-methyl- d-aspartate receptor subunits show region-specific expression of different subunit composition in the human brain , 1996, Neuroscience.

[161]  M. Mcdermott,et al.  A controlled trial of remacemide hydrochloride in Huntington's disease , 1996, Movement disorders : official journal of the Movement Disorder Society.

[162]  M. Beal,et al.  Chronic 3-Nitropropionic Acid Treatment in Baboons Replicates the Cognitive and Motor Deficits of Huntington’s Disease , 1996, The Journal of Neuroscience.

[163]  Charles J. Wilson,et al.  The origins of two-state spontaneous membrane potential fluctuations of neostriatal spiny neurons , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[164]  J. Cooper,et al.  Mitochondrial defect in Huntington's disease caudate nucleus , 1996, Annals of neurology.

[165]  A. Joyner,et al.  Targeted inactivation of the mouse Huntington's disease gene homolog Hdh. , 1996, Cold Spring Harbor symposia on quantitative biology.

[166]  Charles J. Wilson,et al.  Striatal interneurones: chemical, physiological and morphological characterization , 1995, Trends in Neurosciences.

[167]  E. Richfield,et al.  Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients , 1995, Annals of neurology.

[168]  S. Hersch,et al.  Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[169]  P. Calabresi,et al.  Vulnerability of Medium Spiny Striatal Neurons to Glutamate: Role of Na+/K+ ATPase , 1995, The European journal of neuroscience.

[170]  G. Landwehrmeyer,et al.  NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[171]  S. Floresco,et al.  Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes , 1995, Cell.

[172]  E. Hirsch,et al.  Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form , 1995, Nature Genetics.

[173]  C. Portera-Cailliau,et al.  Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[174]  R. Carraway,et al.  Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons , 1995, Neuron.

[175]  I. Kanazawa,et al.  Abnormal gene product identified in Huntington's disease lymphocytes and brain. , 1995, Biochemical and biophysical research communications.

[176]  M. MacDonald,et al.  Huntington's disease gene: Regional and cellular expression in brain of normal and affected individuals , 1995, Annals of neurology.

[177]  A. Parent,et al.  Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop , 1995, Brain Research Reviews.

[178]  S. Folstein,et al.  Early Loss of Neostriatal Striosome Neurons in Huntington's Disease , 1995, Journal of neuropathology and experimental neurology.

[179]  A. Reiner,et al.  Relative Survival of Striatal Projection Neurons and Interneurons after Intrastriatal Injection of Quinolinic Acid in Rats , 1994, Experimental Neurology.

[180]  T. Kuner,et al.  Molecular biology of glutamate receptors , 1994, Progress in Neurobiology.

[181]  B. McEwen,et al.  Molecular aspects of neuropeptide regulation and function in the corpus striatum and nucleus accumbens , 1994, Brain Research Reviews.

[182]  B. Rosen,et al.  Evidence for irnnairment of energy metabofism in vivo in Huntington's disease using localized 1H NMR spectroscopy , 1993, Neurology.

[183]  S. Folstein,et al.  Huntington's disease gene (IT15) is widely expressed in human and rat tissues , 1993, Neuron.

[184]  M. Beal,et al.  Neurochemical substrates of rigidity and chorea in Huntington's disease. , 1993, Brain : a journal of neurology.

[185]  B. Hyman,et al.  Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[186]  J. Penney,et al.  Trinucleotide repeat length instability and age of onset in Huntington's disease , 1993, Nature Genetics.

[187]  M. MacDonald,et al.  Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease , 1993, Nature Genetics.

[188]  M. Hayden,et al.  The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease , 1993, Nature Genetics.

[189]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[190]  O. Isacson,et al.  Age dependence of striatal neuronal death caused by mitochondrial dysfunction. , 1993, Neuroreport.

[191]  C. Gerfen.  The neostriatal mosaic: multiple levels of compartmental organization , 1992, Trends in Neurosciences.

[192]  J. Penney,et al.  Preferential loss of striato‐external pallidal projection neurons in presymptomatic Huntington's disease , 1992, Annals of neurology.

[193]  M. Beal,et al.  Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? , 1992, Annals of neurology.

[194]  N. Kowall,et al.  Neurofilament and neural cell adhesion molecule immunocytochemistry of Huntington's disease striatum , 1992, Annals of neurology.

[195]  M. Hollmann,et al.  Molecular neurobiology of glutamate receptors. , 1992, Annual review of physiology.

[196]  Christopher A. Ross,et al.  Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease , 1991, Neuroscience Letters.

[197]  N W Kowall,et al.  Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[198]  A. Ludolph,et al.  3-Nitropropionic Acid - Exogenous Animal Neurotoxin and Possible Human Striatal Toxin , 1991, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[199]  R. S. Williams,et al.  Morphometric analysis of the prefrontal cortex in Huntington's disease , 1991, Neurology.

[200]  C. Gerfen,et al.  D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. , 1990, Science.

[201]  A. Graybiel.  Neurotransmitters and neuromodulators in the basal ganglia , 1990, Trends in Neurosciences.

[202]  M. Cudkowicz,et al.  Degeneration of pyramidal projection neurons in Huntington's disease cortex , 1990, Annals of neurology.

[203]  J. Penney,et al.  The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.

[204]  Hitoshi Takahashi,et al.  A quantitative investigation of the substantia nigra in Huntington's disease , 1989, Annals of neurology.

[205]  P. Molinoff,et al.  Basic Neurochemistry: Molecular, Cellular and Medical Aspects , 1989 .

[206]  C. Gerfen.  Synaptic organization of the striatum. , 1988, Journal of electron microscopy technique.

[207]  A Jackson,et al.  Chorea and myoclonus in the monkey induced by gamma-aminobutyric acid antagonism in the lentiform complex. The site of drug action and a hypothesis for the neural mechanisms of chorea. , 1988, Brain : a journal of neurology.

[208]  C. Gerfen,et al.  Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: an in situ hybridization histochemistry and fluorescent retrograde tracing study , 1988, Brain Research.

[209]  J. Penney,et al.  Differential loss of striatal projection neurons in Huntington disease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[210]  A. Crossman,et al.  Primate models of dyskinesia: The experimental approach to the study of basal ganglia-related involuntary movement disorders , 1987, Neuroscience.

[211]  R. Lasek,et al.  Cytotypic differences in the protein composition of the axonally transported cytoskeleton in mammalian neurons , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[212]  C. Gerfen,et al.  The neostriatal mosaic: compartmental distribution of calcium-binding protein and parvalbumin in the basal ganglia of the rat and monkey. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[213]  J. B. Martin,et al.  Selective sparing of a class of striatal neurons in Huntington's disease. , 1985, Science.

[214]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[215]  J. Bouyer,et al.  Chemical and structural analysis of the relation between cortical inputs and tyrosine hydroxylase-containing terminals in rat neostriatum , 1984, Brain Research.

[216]  A. Parent,et al.  The occurrence of large acetylcholinesterase-containing neurons in human neostriatum as disclosed in normal and Alzheimer-diseased brains , 1984, Brain Research.

[217]  JohannesP. W. F. Lakke,et al.  Classification of extrapyramidal disorders , 1981, Journal of the Neurological Sciences.

[218]  R. A. Rodda,et al.  Cerebellar atrophy in Huntington's disease , 1981, Journal of the Neurological Sciences.

[219]  A. Parent,et al.  Acetylcholinesterase-containing neurons in cat neostriatum: A morphological and quantitative analysis , 1980, Neuroscience Letters.

[220]  T. Pasik,et al.  Ultrastructure of Golgi-impregnated and gold-toned spiny and aspiny neurons in the monkey neostriatum , 1980, Journal of neurocytology.

[221]  P. Mcgeer,et al.  Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids , 1976, Nature.

[222]  T. Pasik,et al.  A Golgi study of neuronal types in the neostriatum of monkeys , 1976, Brain Research.

[223]  J. Coyle,et al.  Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea , 1976, Nature.

[224]  K. F. Schroeder,et al.  Morphometric studies of the neuropathological changes in choreatic diseases , 1976, Journal of the Neurological Sciences.

[225]  F. Gilles,et al.  Huntington's disease in children , 1973, Neurology.